FASLODEX® (fulvestrant) Injection for intramuscular administration is an estrogen receptor antagonist without known agonist effects. The chemical name is 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol.
FASLODEX is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Media Articles Related to Faslodex (Fulvestrant)
SHAVE a Big Plus in Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2015.05.22]
Dr Kathy Miller makes her top picks of breast cancer studies to watch at ASCO, noting trials in ER-positive and HER2-positive disease--and a small surgical study that may yield big benefits.
Family history has 'no adverse effect' on breast cancer outcomes
Source: Anxiety / Stress News From Medical News Today [2015.05.20]
Women diagnosed and treated for breast cancer under the age of 41 have an outlook just as good with family history of the disease as without - with similar prognosis of recurrence.
A blood test for early detection of breast cancer metastasis
Source: Breast Cancer News From Medical News Today [2015.05.18]
Research findings from Lund University in Sweden now provide new hope for a way of detecting metastases significantly earlier than is currently possible.
siRNA-toting nanoparticles inhibit breast cancer metastasis
Source: Breast Cancer News From Medical News Today [2015.05.15]
Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.
Women with inherited KRAS-variant mutation may be at increased breast cancer risk due to acute estrogen withdrawal
Source: Breast Cancer News From Medical News Today [2015.05.14]
UCLA researchers have discovered that for women with a relatively common inherited mutation, known as the KRAS-variant, abrupt lowering of estrogen may increase their breast cancer risk and impact...
Published Studies Related to Faslodex (Fulvestrant)
Ganitumab with either exemestane or fulvestrant for postmenopausal women with
advanced, hormone-receptor-positive breast cancer: a randomised, controlled,
double-blind, phase 2 trial. 
hormone-receptor-positive breast cancer... INTERPRETATION: Addition of ganitumab to endocrine treatment in women with
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. [2011.01]
BACKGROUND AND PURPOSE: Fulvestrant, an oestrogen receptor (ER) antagonist with no known agonist effects, has shown activity in postmenopausal patients with ER-positive advanced breast cancer recurring or progressing following prior endocrine therapy. This double-blind, double-dummy, randomised phase III study (NCT00327769) was designed to compare the efficacy and safety of fulvestrant versus anastrozole in advanced breast cancer of Chinese postmenopausal women whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment.
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast
cancer: results of a multicentre, double-blind, randomised phase III trial. 
whose disease has progressed following prior endocrine treatment... CONCLUSIONS: These data demonstrate that fulvestrant 250 mg and anastrozole were
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). [2010.12]
BACKGROUND: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy... CONCLUSION: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. [2010.10.20]
PURPOSE: We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy... CONCLUSION: Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity, corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg.
Clinical Trials Related to Faslodex (Fulvestrant)
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer [Completed]
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast
cancer treatment and assess the relationship between dose, exposure, degree of reduction in
tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. [Active, not recruiting]
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant
with the standard dose of 250 mg in postmenopausal women with estrogen receptor positive
advanced breast cancer who have failed on a previous endocrine treatment.
Faslodex and Herceptin, Alone and Combined [Recruiting]
The purpose of this study is to evaluate the the relative anti-tumor efficacy of combined Faslodex and Herceptin therapy as compared with that of Faslodex or Herceptin given alone for first-line treatment in patients with metastatic breast cancer.
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [Recruiting]
The purpose of this study is to find out what effect the combination of fulvestrant
(Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant
Reports of Suspected Faslodex (Fulvestrant) Side Effects
Injection Site Pain (21),
Back Pain (17),
Pain in Extremity (15),
Disease Progression (14),
Hot Flush (13), more >>